Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PepsiCo stevia

This article was originally published in The Tan Sheet

Executive Summary

Latin America will be the first market for SoBe Life, a nutritionally enhanced beverage with stevia-based PureVia all-natural sweetener, PepsiCo and Whole Earth Sweetener announce July 31. Lou Imbrogno, senior VP of worldwide technical operations for Purchase, N.Y.-based PepsiCo, says the PureVia formula is "a potential game-changer among zero-calorie sweeteners" and the company has "ample supply" of stevia from the South American plant. PepsiCo plans to launch PureVia jointly with Whole Earth Sweetener, a subsidiary of Chicago-based Merisant, as a tabletop sweetener in the U.S. this year and introduce it later in other food and beverage products. PureVia will compete with other stevia-based sweeteners in the U.S., including SweetLeaf Sweetener by Wisdom Natural Brands and Truvia, coming from Coca-Cola and Cargill (1"The Tan Sheet" June 30, 2008, p. 11)...

You may also be interested in...



Wisdom’s Unconventional Launch: Stevia Sweetener Without FDA’s GRAS

Wisdom Natural Brands launches a natural sweetener formulation derived from the stevia leaf without FDA affirming the ingredient as safe, an approach industry stakeholders say is best for the firm's business

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel